Wikipedia:Immunai

Immunai is a New York-based biotechnology company mapping and reprogramming immune-system functions using single-cell immunomics and machine learning. Immunai is best known for its development of the world’s largest database of clinically annotated single-cell immune data, termed “AMICA” (the Annotated Multiomic Immune Cell Atlas).

Background
Immunai was founded in 2018 by Luis Voloch, Noam Solomon, Ansuman Satpathy, and Danny Wells. Prior to cofounding Immunai, Solomon finished post-doctoral work in mathematics at Harvard, with Larry Guth at MIT, and in engineering at Palantir Technologies. Voloch, who also studied at MIT, was awarded “Best Thesis” in computer science. The pair cofounded the company with Stanford University cancer immunology professor, Ansuman Satpathy, and Danny Wells, after Solomon read Wells work published in Nature Medicine that described remodeling the immune system after tumor treatment.

In 2021, the company acquired Dropprint, a similar cell-level data developer, and Switzerland-based gene expression data company, Nebion. Following the Nebion acquisition, Immunai appointed immunologist Jacques Banchereau as its CSO. The company is headquartered in New York, with much of its machine learning and software in Tel Aviv, Israel. As of 2021, the company has raised $295 million from Koch Disruptive Technologies, Viola Group, TLV Partners, ICON, 8VC, Alexandria Venture Investments, Schusterman Family Investments, the Duquesne Family Office, Catalio Capital Management, Dexcel Pharma, Piedmont, and others.

Technology
Immunai’s technology maps the immune system at the single cell level, using a multiomic approach that looks at the transcriptome, proteome, epigenome, and TCR/BRC information of each cell. This data is used to map the human immune system. The company’s technology applies machine learning to identify which targets might be most effective, and inversely, which drugs might induce toxic reactions. The technology aims to predict how a patient will respond to a single or combination of potential treatments. The company’s immunological atlas, AMICA, is the largest data set for clinical immunological data. As of 2021, AMICA has mapped hundreds of millions of immune cells. In 2020, the company partnered with Baylor College of Medicine to identify a gene in CAR-NKT-mediated antitumor activity and is purposed with identifying cell therapy candidates in solid tumors. Later that year, Immunai helped researchers at Tel Aviv University identify a combination of COVID-19 antibodies that can serve as both medication for patients and preventive treatment for high-risk populations. Including Baylor College of Medicine and Tel Aviv University, Immunai has a total of 25 academic collaborations and 30 partnerships with Fortune 100 pharmaceutical partners.